Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus

Medcolcanna Organics Inc. Announces Financial Results for the Year Ended December 31, 2019 and for the First Quarter of 2020

BOGOTÁ, Colombia, June 02, 2020 (GLOBE NEWSWIRE) -- Medcolcanna Organics Inc. ("Medcolcanna" or "the "Company") (TSXV: MCCN) announces the filing of its annual financial and operating results for the year ended December 31, 2019 and for the three months ended March 31, 2020. All dollar values in this news release and the Company's financial disclosures are in Canadian dollars, unless otherwise stated.

Key Development

Financial Results & Balances

($CAD dollars)Year ended
December 31, 2019
Three months ended 
March 31, 2020
Cash and cash equivalents2,800,6651,121,360
Working capital2,554,4631,088,802
Property, plant and equipment & right-of-use assets2,127,6862,000,193
Intangible assets1,150,8111,150,811
Total assets6,567,5885,070,628
Cash used in operations4,053,2661,441,283
Net loss 17,214,4681,485,923
Net loss attributable to Medcolcanna shareholders7,214,4681,477,107
Net loss per share, basic & diluted 10.100.02

1) The large difference in Net Loss to Cash used in operations in 2019 is due to non-cash costs incurred during the year, such as stock exchange listing costs, depreciation, share-based compensation and unrealized currency exchange loss.

Management Commentary

Felipe de la Vega, President and CEO of Medcolcanna, commented: "We are pleased to report further progress during the year end and Q1 financial reporting period, including completion of stage one and stage two of the Joint Venture with Dona Blanca.  Subsequent to period end, the Company also received the final approval for commercial production of certain strains of cannabis from its Colombia operations. This is a major step for the Company, as it optimizes cultivation of oil extracts from Cannabis and readies the Company for international export sales in the second and third quarter of 2020.  The Company currently has approximately 5,000 kilograms of dried flower equivalent, from which it will be extracting CBD extract and preparing it for export."

Chris Reid, CFO, commented: "We were able to keep our expenditures inline or below budget for both year end 2019 and the first quarter of 2020, including G&A expenditures of $2.6M and $1.0M, respectively.  The Company is pleased with these expenditure amounts, along with what the Company accomplished operationally. Keeping expenditures low and within budget is always important, but with Coronavirus and other economic uncertainties, it is now more important than ever."

Mr. Reid further added "We are also pleased that Dona Blanca has fully advanced the first and second phase of the Joint Venture and we believe one of the main reasons they entered the Joint Venture was the Company's ability to contain spending, along with the quality of operations at Medcolcanna's facilities in Colombia."

Medcolcanna Investor Relations Contact:

Chris Reid, CFO
Carrera 49b # 93-62
Bogotá, Colombia
Phone: +571 642-9113
Email: info@medcolcanna.com

Forward-Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals for any proposed transaction. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Medcolcanna assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Neither the TSX Venture Exchange Inc. nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

These press releases may also interest you

at 19:35
Technavio has been monitoring the artificial intelligence platforms market and it is poised to grow by USD 12.51 billion during 2020-2024, progressing at a CAGR of over 33% during the forecast period. The report offers an up-to-date analysis...

at 19:32
Duvora has introduced an AI-driven video platform dedicated to virtual luxury home tours as a new way to meet the needs of affluent home buyers in a post COVID-19 world....

at 19:20
Technavio has been monitoring the global building automation software market and it is poised to grow by USD 16.93 billion during 2020-2024, progressing at a CAGR of over 13% during the forecast period. The report offers an up-to-date analysis...

at 19:13
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the...

at 19:02
Intermap Technologies Corporation ("Intermap" or the "Company") today announced a significant new contract and an important new hire. The Company also announced a strategic partnership for Latin America. In...

at 19:00
Znode, an enterprise B2B ecommerce platform, has been awarded six medals in Andy Hoar's Paradigm B2B Combine (Midmarket Edition) including two silver medals and four bronze medals. The 2020 Paradigm B2B Combine evaluates 16 leading B2B ecommerce...

News published on 2 june 2020 at 17:40 and distributed by: